Currently, studies have reported the successful restoration of hearing function in DFNB9 patients through AAV‐mediated gene therapy, highlighting its significant potential for the treatment of deafness.[47, 48] AAV‐Atoh1/GPA/GPAS could regenerate massive iHCs in the GER and IHC region, while fewer HCs were regenerated in the OHC region. Here, GYPA is linked to deafness.